Successes and Challenges of PARP Inhibitors in Cancer Therapy

Saved in:
Bibliographic Details
Published inFrontiers in oncology Vol. 5; p. 222
Main Authors Ricks, Tiffany K., Chiu, Haw-Jyh, Ison, Gwynn, Kim, Geoffrey, McKee, Amy E., Kluetz, Paul, Pazdur, Richard
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 14.10.2015
Subjects
BRCA1
BRCA2
Cancer
Drug Resistance
Homologous Recombination
Oncology
PARP inhibitor
cancer
BRCA1
drug resistance
homologous recombination
BRCA2
PARP inhibitor
Online AccessGet full text

Cover

More Information
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Edited by: Christina Annunziata, National Cancer Institute, USA
Reviewed by: Lawrence Panasci, Jewish General Hospital, Canada; Shiv K. Gupta, Mayo Clinic, USA; Joyce Liu, Dana-Farber Cancer Institute, USA
Specialty section: This article was submitted to Cancer Molecular Targets and Therapeutics, a section of the journal Frontiers in Oncology
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2015.00222